Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that its president and chief executive officer, Daniel O’Connor was selected as a winner in the 2015 Ernst & Young (EY) Entrepreneur Of The Year® in New Jersey. Mr. O’Connor was selected by a panel of independent judges and honored at a special event on June 25 at the Hyatt Regency in New Brunswick, N.J.
“New Jersey is home to many of the best biopharmaceutical companies in the world, so there was an incredible caliber of nominees for this award. The hard work, entrepreneurial spirit and innovation showcased by Dan and his team at Advaxis truly stood out, as they not only grew Advaxis, but helped strengthen New Jersey’s reputation for being a world-leader in the life sciences,” said Debbie Hart, president and CEO of BioNJ. “Today, Dan joins a group of gravity-defying entrepreneurs recognized for contributing to the vibrancy of their community.”
“We are so pleased to see Dan recognized for his leadership and commitment to Advaxis,” said Dr. David Sidransky, chairman of the Advaxis board. “It’s an exciting moment for the entire Advaxis team, which has achieved much and works hard to bring innovative immunotherapies to cancer patients.”
As a New Jersey regional award winner, Mr. O’Connor is now eligible for consideration for the EY Entrepreneur of the Year National awards program. Winners will be announced at the annual gala in Palm Springs, Calif., on November 14, 2015. The EY program identifies entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their business and communities. Now in its 29th year, the program has expanded to recognize business leaders in more than 145 cities in more than 60 countries throughout the world. (Original Source)
Shares of Advaxis Inc closed last Friday at $18.51 . ADXS has a 1-year high of $30.13 and a 1-year low of $2.50. The stock’s 50-day moving average is $22.68 and its 200-day moving average is $14.72.
On the ratings front, Advaxis Inc has been the subject of a number of recent research reports. In a report issued on June 26, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on ADXS, with a price target of $30, which implies an upside of 62.1% from current levels. Separately, on June 25, MLV & Co.’s Ram Selvaraju reiterated a Buy rating on the stock and has a price target of $34.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Swayampakula Ramakanth and Ram Selvaraju have a total average return of 11.2% and 10.2% respectively. Ramakanth has a success rate of 46.3% and is ranked #857 out of 3681 analysts, while Selvaraju has a success rate of 46.5% and is ranked #478.
Advaxis Inc is a clinical development stage biotechnology company. The company is engaged in developing safe & effective immunotherapies for cancer & infectious diseases.